VIR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vir Biotechnology has the Momentum Rank of 4.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Vir Biotechnology's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Momentum Rank falls into.
Thank you for viewing the detailed overview of Vir Biotechnology's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008 |
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Phillip Pang | officer: Chief Medical Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Steven J. Rice | officer: Chief Administrative Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Saira Ramasastry | director | 501 CANAL BLVD., RICHMOND CA 94804 |
Backer Marianne De | officer: Chief Executive Officer | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Ann M. Hanly | officer: Chief Technology Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Sung Lee | officer: Chief Financial Officer | 7000 MARINA BLVD, BRISBANE CA 94005 |
Johanna Friedl-naderer | officer: Chief Business Officer, Global | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
George A Scangos | director, officer: President and CEO | C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
Howard Horn | officer: CFO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Herbert Virgin | officer: EVP, Research & CSO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Janet Napolitano | director | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Robert J More | director | 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001 |
From GuruFocus
By Business Wire • 11-10-2023
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 10-12-2023
By Business Wire • 11-13-2023
By Marketwired • 07-26-2023
By Marketwired • 10-03-2023
By sperokesalga sperokesalga • 06-07-2023
By Marketwired • 09-20-2023
By sperokesalga sperokesalga • 04-11-2023
By sperokesalga sperokesalga • 02-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.